LONDON (AFX) - Provexis PLC said it has entered into a long-term collaboration agreement with Unilever PLC to jointly develop a new concentrated format of its patented Fruitflow heart-health technology for application in Unilever's food product portfolio.

Financial details of the deal were not disclosed.

The partners plan to enter into a global licence arrangement for the technology.

Fruitflow is a patented natural extract from tomato which Provexis said has been shown in human trials to reduce the propensity for aberrant blood clotting that is typically associated with cardiovascular disease and which can lead to heart attack or stroke.

In 2005 the market for heart benefit foods was worth 4 bln usd globally, Provexis added.

Considering the growth potential this share has a target of about 8-10p in the medium tern and is a good buy at current levels

As usual, pls do ur own research.

hope you are all catching this,,,blanche your resistance level has gone,
bid at 1.20, offer at 1.30

Had it's hour of glory.... back now 1.20p

1.2 should act as a good support level now. When we get confirmation this will double. imo

So much for that theory!! Will be irratict til confirmation.

Few profit takers in last 3/4 hr which were bound to get

closing with offer back at 1.20.

good place to be if the volumes stay up

Well we finished blue again bodes well again for tmrw.

started well this morning ! :)

Nothing holding this back now! Even those large two sells didnt even affect it. 10p here we come!! Get in this NOW!! if your just looking in. GL

well my 1.2p is adistant memory. Blow my own trumpet i tipped these at .72 woohoo

Nice one ...well done... let's hope it continues today for a good Monday am start

well done blanche--I bought at .80 and topped up more today hoping for the good news next week!! only holding 169000 unfortunately as no more spare cash--most of my portfolio is in suspended dogs like eel, ive, bb. etc. Gkp is helping the fight back and I'll add here as and when---next week let's hope for a whoosh!!

Well guys no worries here for the future. ps Spread the word!

brill week cant wait til monday!

Blue again! PING

RNS Number : 1486X
Provexis PLC
10 August 2009



10 August 2009




PROVEXIS PLC




('Provexis' or the 'Company')




Recent share price increase




Provexis plc notes the recent movement in its share price. The Board notes that, further to the Company's announcement of 28 May 2009, the final authorisation procedure by the European Commission in relation to Fruitflow, the Company's anti-thrombotic technology, is still under discussion. An update will be provided in due course.




ENQUIRIES




Provexis plc Tel.01753 752 290

Stephen Moon, CEO

Ian Ford, FD




Arbuthnot Tel.020 7012 2000

Tom Griffiths

Richard Johnson

What a day--brilliant we're on our way!!

moneyplus it dont get much better 3p plus tmrw!!!

managed to free up some money in to but not enough

RNS Number : 1886X
Provexis PLC
11 August 2009



11 August 2009

Provexis plc

('Provexis' or the 'Company')




COMMENCEMENT OF CLINICAL TRIAL FOR CROHN'S DISEASE





Provexis plc (PXS.L), the life-science business that discovers, develops and licenses scientifically-proven functional food, medical food and dietary supplement technologies, announces the commencement of a clinical trial for its NSP#3G plantain medical food for Crohns disease patients.

Our results announcement of 9 June 2009 updated the Clinical Trials Authorisation received from the Medicines & Healthcare products Regulatory Agency. We have since successfully completed the necessary pre-trial processes and can now announce a two-centre trial on Crohns disease patients in remission will commence on 18 August 2009. The trial will last for approximately 18 months, with 72 patients taking part.

Crohns disease is an inflammatory disease of the gastrointestinal tract causing a wide variety of symptoms. It affects between 400,000 and 600,000 in North America and estimates of incidence in Northern Europe range from 27 to 48 per 100,000 people. There is no known pharmaceutical or surgical cure for Crohns disease and treatment is restricted to controlling symptoms, maintaining remission and preventing relapse. The Company believes that its medical food technology will successfully maintain remission. The market for Crohns disease treatments is estimated at $1.7bn annually.


With the trial now starting and combined with recently obtained healthy human data, the Company will now commence seeking to identify potential global license or co-development partners to address this substantial market opportunity



Stephen Moon, Chief Executive Officer of Provexis plc, commented:




'Following our recent industry-first European Article 13(5) health claim approval for our Fruitflow anti-thrombotic technology, this further underpins Provexis' capability in developing high quality and scientifically-proven intellectual property. Our new technology addresses an important patient need for a debilitating disease where no effective medical food products for maintaining remission are available currently. Laboratory and human trial work to date has been very promising and we look forward to successful clinical data from this important trial.'







-ends-




For further information please contact:

Stephen Moon, Chief Executive

Provexis plc Tel: 01753 752290




Tom Griffiths/Alasdair Younie Tel: 020 7012 2000

Arbuthnot Securities